1. Home
  2. BAFN vs CGTX Comparison

BAFN vs CGTX Comparison

Compare BAFN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.93

Market Cap

30.9M

Sector

Finance

ML Signal

N/A

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$1.13

Market Cap

94.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAFN
CGTX
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
94.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BAFN
CGTX
Price
$5.93
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
11.9K
637.8K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
1.27%
N/A
EPS Growth
133.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.72
$0.22
52 Week High
$19.00
$3.83

Technical Indicators

Market Signals
Indicator
BAFN
CGTX
Relative Strength Index (RSI) 38.60 50.70
Support Level $5.72 $1.00
Resistance Level $8.57 $1.19
Average True Range (ATR) 0.31 0.07
MACD -0.09 0.02
Stochastic Oscillator 23.75 72.22

Price Performance

Historical Comparison
BAFN
CGTX

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: